<DOC>
	<DOC>NCT02070939</DOC>
	<brief_summary>This single and multiple ascending dose study is the first evaluation of PF-0626414, a Selective Androgen Receptor Modulator in humans. The goal is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in healthy western and Japanese male subjects .</brief_summary>
	<brief_title>Study To Evaluate Safety And Tolerability Of Single And Multiple Ascending Doses Of PF- 06260414 In Healthy Western And Japanese Male Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male between the ages of 21 and 50 years, inclusive (Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG and clinical laboratory tests). Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lbs). Additional inclusion criteria for subjects to be enrolled in Japanese cohort only: Japanese subjects who have four Japanese grandparents born in Japan. Serum total testosterone level &lt;270 or &gt;1070 ng/dL Serum Prostate Specific Antigen (PSA) level &gt;4 ng/mL. Hematocrit &gt;48%. eGFR &gt;150 ml/min/1.73m2.</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>Randomized</keyword>
	<keyword>Double Blind</keyword>
	<keyword>Placebo-Controlled</keyword>
	<keyword>Single and Multiple Dose Escalation</keyword>
	<keyword>Safety Tolerability</keyword>
	<keyword>PK</keyword>
	<keyword>PD</keyword>
	<keyword>PF-06460414</keyword>
</DOC>